Gritstone bio, Inc. (GRTSQ)
| Market Cap | 1.45M |
| Revenue (ttm) | 14.61M |
| Net Income (ttm) | -133.03M |
| Shares Out | 118.11M |
| EPS (ttm) | -1.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,272,800 |
| Open | 0.0200 |
| Previous Close | 0.0200 |
| Day's Range | 0.0100 - 0.0200 |
| 52-Week Range | 0.0100 - 3.1700 |
| Beta | 0.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 6, 2025 |
About Gritstone bio
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatme... [Read more]
Financial Performance
In 2023, Gritstone bio's revenue was $16.34 million, a decrease of -18.05% compared to the previous year's $19.95 million. Losses were -$138.49 million, 15.7% more than in 2022.
Financial StatementsNews
Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update
-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with ...
Bankrupt Gritstone bio in funding talks
Gritstone Bio, which filed for Chapter 11 bankruptcy, is in talks for funding to keep the company running. Read more here.
Covid-Shot Maker Goes Bankrupt After Trailing Pfizer, Moderna
Gritstone Bio Inc., a vaccine developer that once touted its ability to make a next-generation Covid-19 shot, filed for Chapter 11 bankruptcy in Delaware Thursday.
Gritstone bio files for Chapter 11 bankruptcy protection, shares tumble
Gritstone Bio files for Chapter 11 bankruptcy, aims to preserve value and continue with clinical programs despite stock plummeting 90% YTD.
Gritstone downgraded by Jones, B. Riley over cancer vaccine data
Gritstone bio (GRTS) was downgraded by Jones Research and B. Riley on Wednesday, the day after the stock cratered on mixed data for its GRANITE cancer vaccine. Read more here.
Penny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'Insufficient To Excite Many Investors'
On Monday, Gritstone Bio Inc. (NASDAQ: GRTS) revealed interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen-targeting immunotherapy, in frontline micro...
Gritstone stock craters 50% in wake of Phase 2 data, corporate update
Gritstone falls amid Phase 2 Granite data, corporate update
Gritstone (GRTS) stock fell 10% post-market Monday after the company announced Phase 2 data and that it had retained a financial advisor to review potential strategies.